Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
Research & Development
Evaxion Biotech A/S
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Research & Development
-$10.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Research & Development
-kr1.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-36%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Research & Development
-kr1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-23%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Research & Development
-$6.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Research & Development
-€292.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-22%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Research & Development
-kr802.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-6%
|
|
Evaxion Biotech A/S
Glance View
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
See Also
What is Evaxion Biotech A/S's Research & Development?
Research & Development
-10.2m
USD
Based on the financial report for Dec 31, 2024, Evaxion Biotech A/S's Research & Development amounts to -10.2m USD.
What is Evaxion Biotech A/S's Research & Development growth rate?
Research & Development CAGR 5Y
-3%
Over the last year, the Research & Development growth was 12%. The average annual Research & Development growth rates for Evaxion Biotech A/S have been 20% over the past three years , -3% over the past five years .
